Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

33%

1 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A
2(66.7%)
Phase 3
1(33.3%)
3Total
N/A(2)
Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT05231993Not ApplicableEnrolling By Invitation

Clinical Triage and Treatment of Atypical Glandular Cells (AGC) Detected in Screening

Role: collaborator

NCT02948309Phase 3Completed

Mistletoe Therapy in Primary and Recurrent Inoperable Pancreatic Cancer

Role: collaborator

NCT02750124Not ApplicableUnknown

IT-system Development for Reaching Cervix Cancer Screening Non-attenders

Role: collaborator

All 3 trials loaded